Discounted Cash Flow (DCF) Analysis Unlevered

TG Therapeutics, Inc. (TGTX)

$26.56

-0.85 (-3.12%)

All numbers are in Millions, Currency in USD

Stock DCF: -341,219,430.48 | 26.56 | overvalue

Operating Data

Year A/P	2018 Actual	2019 Actual	2020 Actual	2021 Actual	2022 Actual	2023 Projected	2024 Projected	2025 Projected	2026 Projected	2027 Projected
Revenue	0.15	0.15	0.15	6.69	2.78	61.86	1,373.98	30,518.06	677,850.90	15,056,063.02
Revenue (%)
EBITDA	-173.39	-167.48	-272.89	-342.18	-188.17	-51,425.75	-1,142,241.46	-25,370,858.50	-563,523,988.28	-12,516,694,514.47
EBITDA (%)
EBIT	-173.48	-167.58	-273.05	-342.46	-188.14	-51,454.31	-1,142,875.80	-25,384,948.20	-563,836,941.29	-12,523,645,659.98
EBIT (%)
Depreciation	0.09	0.10	0.16	0.28	-0.03	28.56	634.34	14,089.70	312,953.01	6,951,145.51
Depreciation (%)

Balance Sheet Data

Year A/P	2018 Actual	2019 Actual	2020 Actual	2021 Actual	2022 Actual	2023 Projected	2024 Projected	2025 Projected	2026 Projected	2027 Projected
Total Cash	68.81	140.43	605.43	314.76	161.68	67,608.86	1,501,692.04	33,354,783.34	740,858,672.16	16,455,558,007.55
Total Cash (%)
Account Receivables	0.10	0.10	0.10	4.18	1.74	38.66	858.74	19,073.79	423,656.81	9,410,039.39
Account Receivables (%)
Inventories	-	-	-	-	-	-	-	-	-	-
Inventories (%)
Accounts Payable	-	-	37.01	1,628.86	678.18	15,063.46	334,581.65	7,431,549.36	165,065,614.02	3,666,349,451.75
Accounts Payable (%)
Capital Expenditure	-0.09	-0.13	-0.36	-0.40	-2.69	-59.73	-1,326.77	-29,469.62	-654,563.46	-14,538,814.84
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price	$ 26.56
Beta	2.081
Diluted Shares Outstanding	135.41
Cost of Debt
Tax Rate	0.00
After-tax Cost of Debt	85.46%
Risk-Free Rate
Market Risk Premium
Cost of Equity	13.513
Total Debt	11.93
Total Equity	3,596.52
Total Capital	3,608.45
Debt Weighting	0.33
Equity Weighting	99.67
Wacc

Build Up Free Cash

Year A/P	2018 Actual	2019 Actual	2020 Actual	2021 Actual	2022 Actual	2023 Projected	2024 Projected	2025 Projected	2026 Projected	2027 Projected
Revenue	0.15	0.15	0.15	6.69	2.78	61.86	1,373.98	30,518.06	677,850.90	15,056,063.02
EBITDA	-173.39	-167.48	-272.89	-342.18	-188.17	-51,425.75	-1,142,241.46	-25,370,858.50	-563,523,988.28	-12,516,694,514.47
EBIT	-173.48	-167.58	-273.05	-342.46	-188.14	-51,454.31	-1,142,875.80	-25,384,948.20	-563,836,941.29	-12,523,645,659.98
Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIAT	-173.48	-167.58	-273.05	-342.46	-188.14	-51,454.31	-1,142,875.80	-25,384,948.20	-563,836,941.29	-12,523,645,659.98
Depreciation	0.09	0.10	0.16	0.28	-0.03	28.56	634.34	14,089.70	312,953.01	6,951,145.51
Accounts Receivable	-	-	-	-4.09	2.44	-36.92	-820.07	-18,215.05	-404,583.03	-8,986,382.57
Inventories	-	-	-	-	-	-	-	-	-	-
Accounts Payable	-	-	-	1,591.85	-950.68	14,385.28	319,518.19	7,096,967.71	157,634,064.65	3,501,283,837.73
Capital Expenditure	-0.09	-0.13	-0.36	-0.40	-2.69	-59.73	-1,326.77	-29,469.62	-654,563.46	-14,538,814.84
UFCF	-173.48	-167.62	-273.25	1,245.18	-1,139.10	-37,137.13	-824,870.12	-18,321,575.46	-406,949,070.12	-9,038,935,874.15
WACC
PV UFCF						-32,648.03	-637,503.77	-12,448,258.54	-243,071,722.81	-4,746,355,665.32
SUM PV UFCF										-5,002,545,798.47

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%)	13.75
Free cash flow (t + 1)	-9,219,714,591.63
Terminal Value	-78,465,656,098.96
Present Value of Terminal Value	-41,202,406,626.65

Intrinsic Value

Enterprise Value	-46,204,952,425.12
Net Debt	-90.38
Equity Value	-46,204,952,334.74
Shares Outstanding	135.41
Equity Value Per Share	-341,219,430.48